- Home
- RNXT vs IXHL Comparison
RNXT vs IXHL Comparison
Compare RNXT & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNXT | IXHL |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | United States | Australia |
| Employees | N/A | 12 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0M | 37.0M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RNXT | IXHL |
|---|---|---|
| Price | $0.89 | $2.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.25 | N/A |
| AVG Volume (30 Days) | ★ 311.0K | 204.7K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,123,000.00 | $12,000.00 |
| Revenue This Year | $194.66 | N/A |
| Revenue Next Year | $279.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2511.63 | N/A |
| 52 Week Low | $0.70 | $0.16 |
| 52 Week High | $1.45 | $6.39 |
Technical Indicators
Market Signals| Indicator | RNXT | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 33.93 |
| Support Level | $0.89 | $2.78 |
| Resistance Level | $1.07 | $3.68 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 54.09 | 12.94 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.